Agenus | AGEN - Equity Capital And Reserves


Agenus reported $-199.08M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Agenus USD -199.08M 22.15M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Celldex Therapeutics USD 714.56M 258.34M Jun/2026
CSL USD 18.66B 2.75B Dec/2025
Eli Lilly USD 33.88B 2.68B Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
Incyte USD 6.34B 721.58M Jun/2026
Intrexon USD 43.17M 75.33M Jun/2024
J&J USD 84.97B 3.78B Jun/2026
Jiangsu Hengrui CNY 63.63B 2.35B Mar/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck EUR 30.17B 430M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Northwest Biotherapeutics USD -50.54M 58.1M Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Novavax USD -190.71M 45.94M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Veracyte USD 1.39B 44M Jun/2026